968 related articles for article (PubMed ID: 30559466)
1. Myelin oligodendrocyte glycoprotein antibodies in neurological disease.
Reindl M; Waters P
Nat Rev Neurol; 2019 Feb; 15(2):89-102. PubMed ID: 30559466
[TBL] [Abstract][Full Text] [Related]
2. Neuromyelitis optica spectrum disorders with aquaporin-4 and myelin-oligodendrocyte glycoprotein antibodies: a comparative study.
Kitley J; Waters P; Woodhall M; Leite MI; Murchison A; George J; Küker W; Chandratre S; Vincent A; Palace J
JAMA Neurol; 2014 Mar; 71(3):276-83. PubMed ID: 24425068
[TBL] [Abstract][Full Text] [Related]
3. Diagnostic implications of MOG-IgG detection in sera and cerebrospinal fluids.
Matsumoto Y; Kaneko K; Takahashi T; Takai Y; Namatame C; Kuroda H; Misu T; Fujihara K; Aoki M
Brain; 2023 Sep; 146(9):3938-3948. PubMed ID: 37061817
[TBL] [Abstract][Full Text] [Related]
4. MOG Spectrum Disorders and Role of MOG-Antibodies in Clinical Practice.
Hennes EM; Baumann M; Lechner C; Rostásy K
Neuropediatrics; 2018 Feb; 49(1):3-11. PubMed ID: 28859212
[TBL] [Abstract][Full Text] [Related]
5. Myelin-oligodendrocyte-glycoprotein (MOG) autoantibodies as potential markers of severe optic neuritis and subclinical retinal axonal degeneration.
Havla J; Kümpfel T; Schinner R; Spadaro M; Schuh E; Meinl E; Hohlfeld R; Outteryck O
J Neurol; 2017 Jan; 264(1):139-151. PubMed ID: 27844165
[TBL] [Abstract][Full Text] [Related]
6. Myelin oligodendrocyte glycoprotein antibody-associated disease: an immunopathological study.
Takai Y; Misu T; Kaneko K; Chihara N; Narikawa K; Tsuchida S; Nishida H; Komori T; Seki M; Komatsu T; Nakamagoe K; Ikeda T; Yoshida M; Takahashi T; Ono H; Nishiyama S; Kuroda H; Nakashima I; Suzuki H; Bradl M; Lassmann H; Fujihara K; Aoki M;
Brain; 2020 May; 143(5):1431-1446. PubMed ID: 32412053
[TBL] [Abstract][Full Text] [Related]
7. Myelin Oligodendrocyte Glycoprotein: Deciphering a Target in Inflammatory Demyelinating Diseases.
Peschl P; Bradl M; Höftberger R; Berger T; Reindl M
Front Immunol; 2017; 8():529. PubMed ID: 28533781
[TBL] [Abstract][Full Text] [Related]
8. Possible clinical role of MOG antibody testing in children presenting with acute neurological symptoms.
Musso G; Nosadini M; Gallo N; Sartori S; Seguso M; Plebani M
Neurol Sci; 2020 Sep; 41(9):2553-2559. PubMed ID: 32242290
[TBL] [Abstract][Full Text] [Related]
9. Neuromyelitis optica spectrum disorders with antibodies to myelin oligodendrocyte glycoprotein or aquaporin-4: Clinical and paraclinical characteristics in Algerian patients.
Bouzar M; Daoudi S; Hattab S; Bouzar AA; Deiva K; Wildemann B; Reindl M; Jarius S
J Neurol Sci; 2017 Oct; 381():240-244. PubMed ID: 28991690
[TBL] [Abstract][Full Text] [Related]
10. Myelin oligodendrocyte glycoprotein and aquaporin-4 antibodies are highly specific in children with acquired demyelinating syndromes.
Duignan S; Wright S; Rossor T; Cazabon J; Gilmour K; Ciccarelli O; Wassmer E; Lim M; Hemingway C; Hacohen Y
Dev Med Child Neurol; 2018 Sep; 60(9):958-962. PubMed ID: 29468668
[TBL] [Abstract][Full Text] [Related]
11. Seroprevalence of MOG and AQP4 Antibodies and Outcomes in an Indian Cohort of Pediatric Acquired Demyelinating Syndromes.
Sankhyan N; Rawat A; Vyas S; Sahu JK; Bhagwat C; Madaan P; Saini L; Saini AG; Suthar R; Sukhija J; Jayashree M
Neuropediatrics; 2022 Oct; 53(5):351-357. PubMed ID: 35617966
[TBL] [Abstract][Full Text] [Related]
12. Clinical spectrum and IgG subclass analysis of anti-myelin oligodendrocyte glycoprotein antibody-associated syndromes: a multicenter study.
Mariotto S; Ferrari S; Monaco S; Benedetti MD; Schanda K; Alberti D; Farinazzo A; Capra R; Mancinelli C; De Rossi N; Bombardi R; Zuliani L; Zoccarato M; Tanel R; Bonora A; Turatti M; Calabrese M; Polo A; Pavone A; Grazian L; Sechi G; Sechi E; Urso D; Delogu R; Janes F; Deotto L; Cadaldini M; Bianchi MR; Cantalupo G; Reindl M; Gajofatto A
J Neurol; 2017 Dec; 264(12):2420-2430. PubMed ID: 29063242
[TBL] [Abstract][Full Text] [Related]
13. Diagnostic algorithm for relapsing acquired demyelinating syndromes in children.
Hacohen Y; Mankad K; Chong WK; Barkhof F; Vincent A; Lim M; Wassmer E; Ciccarelli O; Hemingway C
Neurology; 2017 Jul; 89(3):269-278. PubMed ID: 28615429
[TBL] [Abstract][Full Text] [Related]
14. Complement activating antibodies to myelin oligodendrocyte glycoprotein in neuromyelitis optica and related disorders.
Mader S; Gredler V; Schanda K; Rostasy K; Dujmovic I; Pfaller K; Lutterotti A; Jarius S; Di Pauli F; Kuenz B; Ehling R; Hegen H; Deisenhammer F; Aboul-Enein F; Storch MK; Koson P; Drulovic J; Kristoferitsch W; Berger T; Reindl M
J Neuroinflammation; 2011 Dec; 8():184. PubMed ID: 22204662
[TBL] [Abstract][Full Text] [Related]
15. MOG encephalomyelitis: international recommendations on diagnosis and antibody testing.
Jarius S; Paul F; Aktas O; Asgari N; Dale RC; de Seze J; Franciotta D; Fujihara K; Jacob A; Kim HJ; Kleiter I; Kümpfel T; Levy M; Palace J; Ruprecht K; Saiz A; Trebst C; Weinshenker BG; Wildemann B
J Neuroinflammation; 2018 May; 15(1):134. PubMed ID: 29724224
[TBL] [Abstract][Full Text] [Related]
16. Myelin oligodendrocyte glycoprotein antibodies in neuromyelitis optica spectrum disorder.
Ungureanu A; de Seze J; Ahle G; Sellal F
Rev Neurol (Paris); 2018 Dec; 174(10):675-679. PubMed ID: 30293882
[TBL] [Abstract][Full Text] [Related]
17. E.U. paediatric MOG consortium consensus: Part 1 - Classification of clinical phenotypes of paediatric myelin oligodendrocyte glycoprotein antibody-associated disorders.
Bruijstens AL; Lechner C; Flet-Berliac L; Deiva K; Neuteboom RF; Hemingway C; Wassmer E; ; Baumann M; Bartels F; Finke C; Adamsbaum C; Hacohen Y; Rostasy K
Eur J Paediatr Neurol; 2020 Nov; 29():2-13. PubMed ID: 33162302
[TBL] [Abstract][Full Text] [Related]
18. The occurrence of myelin oligodendrocyte glycoprotein antibodies in aquaporin-4-antibody seronegative Neuromyelitis Optica Spectrum Disorder: A systematic review and meta-analysis.
Li X; Zhang C; Jia D; Fan M; Li T; Tian DC; Liu Y; Shi FD
Mult Scler Relat Disord; 2021 Aug; 53():103030. PubMed ID: 34118585
[TBL] [Abstract][Full Text] [Related]
19. Clinicoradiological comparative study of Aquaporin-4-IgG seropositive neuromyelitis optica spectrum disorder (NMOSD) and MOG antibody associated disease (MOGAD): A prospective observational study and review of literature.
Nagireddy RBR; Kumar A; Singh VK; Prasad R; Pathak A; Chaurasia RN; Mishra VN; Joshi D
J Neuroimmunol; 2021 Dec; 361():577742. PubMed ID: 34655992
[TBL] [Abstract][Full Text] [Related]
20. Prognostic relevance of MOG antibodies in children with an acquired demyelinating syndrome.
Hennes EM; Baumann M; Schanda K; Anlar B; Bajer-Kornek B; Blaschek A; Brantner-Inthaler S; Diepold K; Eisenkölbl A; Gotwald T; Kuchukhidze G; Gruber-Sedlmayr U; Häusler M; Höftberger R; Karenfort M; Klein A; Koch J; Kraus V; Lechner C; Leiz S; Leypoldt F; Mader S; Marquard K; Poggenburg I; Pohl D; Pritsch M; Raucherzauner M; Schimmel M; Thiels C; Tibussek D; Vieker S; Zeches C; Berger T; Reindl M; Rostásy K;
Neurology; 2017 Aug; 89(9):900-908. PubMed ID: 28768844
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
